Tildrakizumab for symptoms and quality of life in Canadians with moderate-to-severe plaque psoriasis (Fitzpatrick III+)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-centre, non-interventional, open-label prospective observational study conducted across Canada over 52 weeks. About 80 adults with moderate-to-severe plaque psoriasis (Fitzpatrick III+) who are initiating tildrakizumab as part of routine care will be enrolled. Data collection will focus on patient-reported outcomes, safety events, and real-world effectiveness while patients receive standard clinical care; there is no randomization or study-assigned treatment. The study aims to fill gaps in Canadian real-world evidence, especially for patients with darker skin phototypes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults aged 18 years or older.
2. Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \>/=3%).
3. Candidate for phototherapy and/or systemic therapy.
4. Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.

   a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.
5. Must be able to read, understand, and communicate in English.
6. Must be willing to participate in the study and capable to provide informed consent
7. Able to comply with all study procedures and attend all study visits

Exclusion Criteria:

1. Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.
2. Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)
3. Diagnosis of only palmoplantar psoriasis
4. Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments
5. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.
6. Prior (within 30 days) or actively participating in other interventional clinical trial(s).
7. Unable or unwilling to comply with study procedures including completing questionnaire.
8. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results

Where it's running

• Benchmark Dermatology
  Burlington, Ontario, Canada Recruiting
• Locke Dermatology
  Hamilton, Ontario, Canada Recruiting
• Panorama Dermatology Clinic
  Kanata, Ontario, Canada Recruiting
• Factor Dermatology
  Ottawa, Ontario, Canada Recruiting
• Vital Medical Centre
  Ottawa, Ontario, Canada Recruiting
• Elevate Dermatology
  Pickering, Ontario, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retinal Vessel Density and Foveal Avascular Zone Size in Psoriatic Arthritis

  This study tests whether retinal blood vessel density and the size of the foveal avascular zone differ between people with psoriatic arthritis, people with psoriasis, and healthy individuals using non-invasive eye imaging.

  Recruiting Bursa Yuksek Ihtisas Training and Research Hospital · Bursa, Yıldırım · NCT07858591

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• HL40626S tablets in healthy adults: a first-in-human dose study

  This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.

  Recruiting Phase 1 HighsLab Therapeutics Inc. · Melbourne, Victoria and 1 other locations · NCT07736586

• Global psoriasis care patterns and outcomes (observational)

  This study tests how psoriasis is managed across different health systems by following patients over time to see care access, treatments, disease severity, and quality of life.

  Recruiting University of Zurich · Zurich · NCT07634016

• S-4321 in adults with autoimmune or immune-mediated diseases

  This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.

  Recruiting at 2 sites Phase 1 Seismic Therapeutic AU Pty Ltd · Charlestown, New South Wales and 1 other locations · NCT07455578

• Semaglutide plus topical steroid/calcipotriol for plaque psoriasis in adults with overweight, obesity, or type 2 diabetes

  This trial will test whether taking oral semaglutide along with a topical steroid/calcipotriol cream improves skin symptoms and reduces metabolic inflammation in adults with plaque psoriasis who are overweight, obese, or have type 2 diabetes.

  Recruiting Phase 4 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, N.L. · NCT07401992

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.